Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male citizens of Asian countries and Australia are encouraged to enroll in the study~* patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study~* diagnosis of premature ejaculation (PE) according to the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) for at least 6 months before study initiation~* history of intravaginal ejaculatory latency time (IELT) of \<2 minutes in at least 3 out of 4 events~* patient's partner must have a negative urine pregnancy test at time of screening~* Exclusion Criteria:~* Not taken dapoxetine or participated in another study investigating pharmacologic treatment of PE within the last 3 months~* no history of any medical events that are associated with the development of PE~* not taken another investigational drug within 1 month, or used an experimental medical device within 6 months of study initiation~* no positive diagnosis of depressive or anxiety disorder, manic episode, panic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, alcohol abuse and dependence, schizophrenia, or other psychotic disorders~* no known allergy or hypersensitivity to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).